Side Effects Dampen Neurologists’ Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change
You may also be interested in...
Novartis Finds FREEDOM From Fingolimod Concerns In Second Phase III, Limits Dose To Play It Safe
FREEDOMS clinical trial show lower levels of cancer than first Phase III trial, but Novartis goes one step further by eliminating the highest dose of its oral MS therapy and thus minimizing the side effects associated with FTY720.
Safety Remains Front-Line Concern For Oral MS Drugs
Two drugs in a race to become the first oral treatment for relapsing forms of multiple sclerosis have high safety hurdles to overcome, obstacles that may knock them both out of the running as first-line treatments.
Genzyme Plays Up Emerging Blood Cancer Business In R&D Review
Genzyme has set its sights on emerging as a hematologic cancers specialist – a strategy made possible by a deal made in March, when it gained full rights to Campath from partner Bayer and brought in two additional blood cancer therapies.